{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:07:29Z","timestamp":1781716049726,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78221-9","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T03:03:30Z","timestamp":1730516610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Renshi","family":"Kawakatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Tadagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumichi","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"78221_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"22","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults. 2022 recommendations from an international expert panel on behalf of the ELN. Blood 22, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"78221_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"78221_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"78221_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn, E. et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 37, 2187\u20132196 (2023).","journal-title":"Leukemia"},{"key":"78221_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"78221_CR6","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).","journal-title":"Blood Cancer J."},{"key":"78221_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo, S., Damato, A., Alfano, L. & Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Cancer Res. 37, 36 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"78221_CR8","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian, H. et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422\u20134429 (2010).","journal-title":"Blood"},{"key":"78221_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fonc.2015.00280","volume":"5","author":"K Pettit","year":"2015","unstructured":"Pettit, K. & Odenike, O. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front. Oncol. 5, 280 (2015).","journal-title":"Front. Oncol."},{"key":"78221_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood 126, 291\u2013299 (2015).","journal-title":"Blood"},{"key":"78221_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"78221_CR12","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.3390\/cancers13225608","volume":"13","author":"S Garciaz","year":"2021","unstructured":"Garciaz, S., Saillard, C., Hicheri, Y., Hospital, M. A. & Vey, N. Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance. Cancers (Basel) 13, 5608 (2021).","journal-title":"Cancers (Basel)"},{"key":"78221_CR13","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater, A. P. et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study. J. Clin. Oncol. 38, 4042\u20134054 (2020).","journal-title":"J. Clin. Oncol."},{"key":"78221_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"78221_CR15","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"78221_CR16","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.3390\/cancers15143589","volume":"15","author":"E Oyogoa","year":"2023","unstructured":"Oyogoa, E., Traer, E., Tyner, J. & Lachowiez, C. Building on foundations: Venetoclax-based combinations in the treatment of acute myeloid leukemia. Cancers (Basel) 15, 3589 (2023).","journal-title":"Cancers (Basel)"},{"key":"78221_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2643-3230.BCD-23-0014","volume":"4","author":"CA Eide","year":"2023","unstructured":"Eide, C. A. et al. Clinical correlates of venetoclax-based combination sensitivities to augment acute myeloid leukemia therapy. Blood Cancer Discov. 4, 452\u2013467 (2023).","journal-title":"Blood Cancer Discov."},{"key":"78221_CR18","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1038\/s41598-024-55286-0","volume":"14","author":"R Kawakatsu","year":"2024","unstructured":"Kawakatsu, R., Tadagaki, K., Yamasaki, K. & Yoshida, T. Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate. Sci. Rep. 14, 4975 (2024).","journal-title":"Sci. Rep."},{"key":"78221_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99\u2013163 (2007).","journal-title":"Physiol. Rev."},{"key":"78221_CR20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.cdd.4401088","volume":"9","author":"G Van Loo","year":"2002","unstructured":"Van Loo, G. et al. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell. Death Differ. 9, 1031\u20131042 (2002).","journal-title":"Cell. Death Differ."},{"key":"78221_CR21","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","volume":"62","author":"H Cong","year":"2019","unstructured":"Cong, H. et al. Inhibitor of apoptosis protein (IAP) antagonists in Anticancer Agent Discovery: current status and perspectives. J. Med. Chem. 62, 5750\u20135772 (2019).","journal-title":"J. Med. Chem."},{"key":"78221_CR22","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.3390\/molecules28248141","volume":"28","author":"N Georgiou","year":"2023","unstructured":"Georgiou, N. et al. Quercetin: a potential polydynamic drug. Molecules 28, 8141 (2023).","journal-title":"Molecules"},{"key":"78221_CR23","doi-asserted-by":"crossref","unstructured":"Andres, S. et al. Safety aspects of the use of quercetin as a dietary supplement. Mol. Nutr. Food Res. 62, 1700447 (2018).","DOI":"10.1002\/mnfr.201700447"},{"key":"78221_CR24","doi-asserted-by":"publisher","first-page":"e000392","DOI":"10.1136\/bmjresp-2018-000392","volume":"7","author":"MK Han","year":"2020","unstructured":"Han, M. K., Barreto, T. A., Martinez, F. J., Comstock, A. T. & Sajjan, U. S. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir. Res. 7, e000392 (2020).","journal-title":"BMJ Open Respir. Res."},{"key":"78221_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ptr.5518","volume":"30","author":"NT Lu","year":"2016","unstructured":"Lu, N. T. et al. A phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavonoid antivirals in patients with chronic hepatitis C. Phytother. Res. 30, 160\u2013168 (2016).","journal-title":"Phytother. Res."},{"key":"78221_CR26","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/ijms20133177","volume":"20","author":"M Reyes-Farias","year":"2019","unstructured":"Reyes-Farias, M. & Carrasco-Pozo, C. The anticancer effect of quercetin: molecular implications in cancer metabolism. Int. J. Mol. Sci. 20, 3177 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"78221_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12935-022-02677-w","volume":"22","author":"P Asgharian","year":"2022","unstructured":"Asgharian, P. et al. Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. Cancer Cell Int. 22, 257 (2022).","journal-title":"Cancer Cell Int."},{"key":"78221_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/07357900802337191","volume":"27","author":"BE Shan","year":"2009","unstructured":"Shan, B. E., Wang, M. X. & Li, R. Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt\/beta-catenin signaling pathway. Cancer Investig. 27, 604\u2013612 (2009).","journal-title":"Cancer Investig."},{"key":"78221_CR29","first-page":"1299","volume":"14","author":"T Yoshida","year":"2005","unstructured":"Yoshida, T. et al. Quercetin induces gadd45 expression through a p53-independent pathway. Oncol. Rep. 14, 1299\u20131303 (2005).","journal-title":"Oncol. Rep."},{"key":"78221_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/cpr.12017","volume":"46","author":"K Bishayee","year":"2013","unstructured":"Bishayee, K. et al. Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2\/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell Prolif. 46, 153\u2013163 (2013).","journal-title":"Cell Prolif."},{"key":"78221_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11596-014-1345-6","volume":"34","author":"T Xiang","year":"2014","unstructured":"Xiang, T., Fang, Y. & Wang, S. X. Quercetin suppresses HeLa cells by blocking PI3K\/Akt pathway. J. Huazhong Univ. Sci. Technol. Med. Sci. 34, 740\u2013744 (2014).","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"78221_CR32","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1007\/s11033-012-1621-0","volume":"39","author":"Z Yuan","year":"2012","unstructured":"Yuan, Z. et al. Quercetin-induced apoptosis of HL-60 cells by reducing PI3K\/Akt. Mol. Biol. Rep. 39, 7785\u20137793 (2012).","journal-title":"Mol. Biol. Rep."},{"key":"78221_CR33","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1039\/C4FO00484A","volume":"5","author":"M Mojsin","year":"2014","unstructured":"Mojsin, M., Vicentic, J. M., Schwirtlich, M., Topalovic, V. & Stevanovic, M. Quercetin reduces pluripotency, migration and adhesion of human teratocarcinoma cell line NT2\/D1 by inhibiting Wnt\/\u03b2-catenin signaling. Food Funct. 5, 2564\u20132573 (2014).","journal-title":"Food Funct."},{"key":"78221_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ptr.5061","volume":"28","author":"L Senggunprai","year":"2014","unstructured":"Senggunprai, L., Kukongviriyapan, V., Prawan, A. & Kukongviriyapan, U. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK\/STAT signaling pathway. Phytother. Res. 28, 841\u2013848 (2014).","journal-title":"Phytother. Res."},{"key":"78221_CR35","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1002\/cam4.2388","volume":"8","author":"L Wu","year":"2019","unstructured":"Wu, L. et al. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2\/STAT3 signaling pathway. Cancer Med. 8, 4806\u20134820 (2019).","journal-title":"Cancer Med."},{"key":"78221_CR36","doi-asserted-by":"publisher","first-page":"e51764","DOI":"10.1371\/journal.pone.0051764","volume":"7","author":"G Wang","year":"2012","unstructured":"Wang, G., Zhang, J., Liu, L., Sharma, S. & Dong, Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53\/Bcl-xl. PLoS One 7, e51764 (2012).","journal-title":"PLoS One"},{"key":"78221_CR37","doi-asserted-by":"publisher","first-page":"e54255","DOI":"10.1371\/journal.pone.0054255","volume":"8","author":"ST Chan","year":"2013","unstructured":"Chan, S. T., Yang, N. C., Huan, C. S., Liao, J. W. & Yeh, S. L. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One. 8, e54255 (2013).","journal-title":"PLoS One"},{"key":"78221_CR38","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1055-9965.EPI-12-0745","volume":"21","author":"TK Lam","year":"2012","unstructured":"Lam, T. K. et al. Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiol. Biomark. Prev. 21, 2176\u20132184 (2012).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"78221_CR39","doi-asserted-by":"publisher","first-page":"6664","DOI":"10.1039\/D1FO00851J","volume":"12","author":"X Zang","year":"2021","unstructured":"Zang, X., Cheng, M., Zhang, X. & Chen, X. Quercetin nanoformulations: a promising strategy for tumor therapy. Food Funct. 12, 6664\u20136681 (2021).","journal-title":"Food Funct."},{"key":"78221_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2016.08.055","volume":"84","author":"M Lou","year":"2016","unstructured":"Lou, M. et al. Quercetin nanoparticles induced autophagy and apoptosis through AKT\/ERK\/Caspase-3 signaling pathway in human neuroglioma cells: in vitro and in vivo. Biomed. Pharmacother. 84, 1\u20139 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"78221_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.fct.2014.03.018","volume":"68","author":"K Valentov\u00e1","year":"2014","unstructured":"Valentov\u00e1, K., Vrba, J., Banc\u00ed\u0159ov\u00e1, M., Ulrichov\u00e1, J. & K\u0159en, V. Isoquercitrin: pharmacology, toxicology, and metabolism. Food Chem. Toxicol. 68, 267\u2013282 (2014).","journal-title":"Food Chem. Toxicol."},{"key":"78221_CR42","doi-asserted-by":"publisher","first-page":"e6665","DOI":"10.7717\/peerj.6665","volume":"7","author":"H Yin","year":"2019","unstructured":"Yin, H., Ma, J., Han, J., Li, M. & Shang, J. Pharmacokinetic comparison of quercetin, isoquercitrin, and quercetin-3-O-beta-D-glucuronide in rats by HPLC-MS. PeerJ. 7, e6665 (2019).","journal-title":"PeerJ"},{"key":"78221_CR43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2008.07261.x","volume":"142","author":"A Kohlmann","year":"2008","unstructured":"Kohlmann, A. et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the microarray innovations in LEukemia study prephase. Br. J. Haematol. 142, 802\u2013807 (2008).","journal-title":"Br. J. Haematol."},{"key":"78221_CR44","doi-asserted-by":"publisher","first-page":"D881","DOI":"10.1093\/nar\/gky1076","volume":"47","author":"FO Bagger","year":"2019","unstructured":"Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881\u2013D885 (2019).","journal-title":"Nucleic Acids Res."},{"key":"78221_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41416-018-0140-8","volume":"119","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Characteristics of the Cancer Genome Atlas cases relative to U.S. general population cancer cases. Br. J. Cancer. 119, 885\u2013892 (2018).","journal-title":"Br. J. Cancer"},{"key":"78221_CR46","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 2529\u20132537 (2010).","journal-title":"J. Clin. Oncol."},{"key":"78221_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1024116916932","volume":"8","author":"TM Caserta","year":"2003","unstructured":"Caserta, T. M., Smith, A. N., Gultice, A. D., Reedy, M. A. & Brown, T. L. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345\u2013352 (2003).","journal-title":"Apoptosis"},{"key":"78221_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cancers16061091","volume":"16","author":"S Garciaz","year":"2024","unstructured":"Garciaz, S., Hospital, M. A., Collette, Y. & Vey, N. Venetoclax resistance in acute myeloid leukemia. Cancers (Basel) 16, 1091 (2024).","journal-title":"Cancers (Basel)"},{"key":"78221_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"78221_CR50","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/blood.V79.9.2378.2378","volume":"79","author":"K Sugimoto","year":"1992","unstructured":"Sugimoto, K. et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79, 2378\u20132383 (1992).","journal-title":"Blood"},{"key":"78221_CR51","doi-asserted-by":"publisher","first-page":"19181","DOI":"10.1074\/jbc.270.32.19181","volume":"270","author":"M Akashi","year":"1995","unstructured":"Akashi, M. et al. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J. Biol. Chem. 270, 19181\u201319187 (1995).","journal-title":"J. Biol. Chem."},{"key":"78221_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/ijo.2021.5296","volume":"60","author":"T Yoshida","year":"2022","unstructured":"Yoshida, T. et al. Tumor necrosis factorrelated apoptosisinducing ligand is a novel transcriptional target of runtrelated transcription factor 1. Int. J. Oncol. 60, 6 (2022).","journal-title":"Int. J. Oncol."},{"key":"78221_CR53","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.bbadva.2022.100047","volume":"2","author":"A Matsumoto","year":"2022","unstructured":"Matsumoto, A. et al. C11orf21, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO. BBA Adv. 2, 100047 (2022).","journal-title":"BBA Adv."},{"key":"78221_CR54","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s13577-020-00347-5","volume":"33","author":"F Kasai","year":"2020","unstructured":"Kasai, F. et al. Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations. Hum. Cell 33, 868\u2013876 (2020).","journal-title":"Hum. Cell"},{"key":"78221_CR55","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman, G. J. et al. VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors\u2014efficacy, safety, and biomarker results. Clin. Cancer Res. 28, 3256\u20133267 (2022).","journal-title":"Clin. Cancer Res."},{"key":"78221_CR56","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"78221_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms22010204","volume":"22","author":"M Olivas-Aguirre","year":"2020","unstructured":"Olivas-Aguirre, M., Torres-L\u00f3pez, L., Pottosin, I. & Dobrovinskaya, O. Phenolic compounds cannabidiol, curcumin and quercetin cause mitochondrial dysfunction and suppress acute lymphoblastic leukemia cells. Int. J. Mol. Sci. 22, 20 (2020).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78221-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:06:45Z","timestamp":1730786805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78221-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78221"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78221-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4807182\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26418"}}